Archives
-
EZ Cap Cy5 Firefly Luciferase mRNA: Dual Reporter Power in C
2026-04-25
EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes gene expression and mRNA delivery studies by combining robust bioluminescence with direct Cy5 fluorescence tracking. Its Cap1 structure and 5-moUTP modification optimize translation and minimize innate immune activation, enabling high-sensitivity, reproducible workflows across cell and tissue models.
-
LNP-NamiRNA Suppresses Pancreatic Cancer via Dual Pathways
2026-04-24
Yu et al. demonstrate that lipid nanoparticle (LNP)-delivered mir-200c, acting as a nuclear activating miRNA (NamiRNA), inhibits pancreatic cancer proliferation and migration through two distinct mechanisms: transcriptional activation of PTPN6 and post-transcriptional repression of CDH17. This dual regulatory action highlights NamiRNA-based therapeutics as a promising avenue for treating aggressive malignancies.
-
Proteinase K (K1037): Ensuring DNA Integrity in Molecular As
2026-04-24
This article examines real-world laboratory challenges in cell viability and DNA-based assays, revealing how Proteinase K (SKU K1037) delivers reproducible, high-integrity results. Drawing on peer-reviewed data and validated protocols, the content guides researchers in optimizing protein hydrolysis, contaminant removal, and workflow reliability with APExBIO’s recombinant Proteinase K.
-
AMPK Suppresses Rather Than Activates Autophagy Under Energy
2026-04-23
This study overturns the prevailing model of autophagy regulation, demonstrating that AMPK inhibits, rather than promotes, autophagy initiation during glucose starvation by directly suppressing ULK1 activity. These findings refine the understanding of energy stress signaling, with broad implications for metabolic and cellular homeostasis research.
-
Light-Inducible RNA-Releasing Protein Enables Optogenetic Ge
2026-04-23
The referenced study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that functions as a gene switch for translational regulation in mammalian cells. This optogenetic tool allows for spatially and temporally controlled gene therapy, particularly benefiting chronic metabolic and retinal diseases requiring on-demand therapeutic actions.
-
Drug Repurposing for DNA Repair Pathway Control in CRISPR Ed
2026-04-22
This study comprehensively screens FDA-approved drugs for their ability to influence double-strand DNA break (DSB) repair pathway choice in human stem cells, with implications for genome editing precision and synthetic lethality in cancer therapy. By mapping drug effects on nonhomologous end joining, microhomology-mediated end joining, and homology-directed repair, the research sets a foundation for tailored gene editing and therapeutic strategies.
-
Afatinib (BIBW 2992): Precision ErbB Inhibition in Cancer Mo
2026-04-22
Afatinib (BIBW 2992) empowers researchers to dissect ErbB-driven signaling in physiologically relevant 3D assembloid models, overcoming resistance mechanisms that limit other TKIs. Its irreversible inhibition profile delivers robust, reproducible results—especially in complex tumor-stroma co-cultures that mirror patient-specific cancer biology.
-
GPR107 Deficiency Drives Collagen IV Accumulation in Diabeti
2026-04-21
Xu et al. elucidate how loss of GPR107 in podocytes aggravates diabetic nephropathy by disrupting collagen type IV homeostasis and amplifying pro-fibrotic signaling via impaired angiotensin II receptor trafficking. Their mechanistic findings clarify podocyte endocytosis's role in glomerular basement membrane thickening and support targeted intervention strategies.
-
Selective Inhibition of SARS-CoV-2 3CLpro by Merbromin: Insi
2026-04-21
This study identifies Merbromin as a mixed-type, highly selective inhibitor of SARS-CoV-2 3-chymotrypsin-like protease (3CLpro), without significant inhibition of broad-spectrum serine proteases such as Proteinase K. Its findings provide a new lead scaffold for antiviral drug development targeting viral proteases.
-
Cyanine 5-dCTP: Advanced Fluorescent Labeling for DNA Synthe
2026-04-20
Cyanine 5-dCTP (Cy5-dCTP) enables precise, high-sensitivity fluorescent DNA labeling in enzymatic oligonucleotide synthesis, PCR, and advanced probe generation. Explore robust experimental workflows, data-backed protocol parameters, and troubleshooting strategies that maximize reproducibility and signal-to-noise for next-generation nucleic acid detection.
-
Stattic in Translational Cancer Biology: STAT3 Inhibition an
2026-04-20
Explore how Stattic, a leading STAT3 inhibitor, enables advanced cancer biology research by dissecting the interplay between STAT3 signaling and gut microbiome-driven resistance mechanisms. This article offers a unique translational perspective on optimizing apoptosis induction and radiosensitization assays in oncology.
-
Proteomic Impact of HSP90 Inhibition in Lung Adenocarcinoma
2026-04-19
This study systematically investigates how pharmacological inhibition of HSP90 alters the proteomic landscape of lung adenocarcinoma cells, revealing key pathways and potential biomarkers of response. The findings provide a foundation for refining chaperone-targeted strategies and identifying combinatorial approaches in cancer research.
-
Pharmacokinetic Variability of CSBTA in MASH: Mechanisms and
2026-04-18
This study systematically investigates the integrated pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice with metabolic dysfunction-associated steatohepatitis (MASH). Through advanced analytical and cellular models, it reveals how pathological liver status, enzyme, and transporter changes drive significant variability in CSBTA exposure, informing rational dosage design for MASLD/MASH treatment.
-
CRISPR Disruption of scaRNA1 Alters U2 Pseudouridylation & S
2026-04-17
This study demonstrates that targeted CRISPR-Cas9 disruption of scaRNA1 in HEK293T cells leads to a marked reduction in pseudouridylation at U2 snRNA residue U89, which in turn perturbs global mRNA splicing patterns and transcript isoform diversity. The findings provide mechanistic insight into how noncoding RNA dysfunction may contribute to developmental disorders and highlight the critical regulatory role of RNA-guided modifications in spliceosomal function.
-
SMYD2 Inhibition Alleviates Cisplatin-Induced Renal Fibrosis
2026-04-16
This study demonstrates that pharmacological inhibition of SMYD2, using selective inhibitors such as AZ505, can protect against cisplatin-induced renal fibrosis and inflammation in vivo and in vitro. These findings highlight the critical role of SMYD2 in chronic kidney disease pathogenesis and point to epigenetic modulation as a promising therapeutic strategy.